The antioxidant edaravone attenuates pressure overload–induced left ventricular hypertrophy
I Tsujimoto, S Hikoso, O Yamaguchi, K Kashiwase… - …, 2005 - Am Heart Assoc
The free radical scavenger 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) is used to treat
patients with ischemic brain damage. We and others reported previously that in vitro and in …
patients with ischemic brain damage. We and others reported previously that in vitro and in …
Left ventricular hypertrophy induced by abdominal aortic banding and its prevention by angiotensin receptor blocker telmisartan—a proteomic analysis
L Liu, W Wang, X Meng, J Gao, H Wu, P Wang… - Journal of physiology …, 2010 - Springer
Cardiac hypertrophy is frequently caused by pressure overload (ie, high blood pressure or
hypertension) and can lead to heart failure. The major objective of the present study was to …
hypertension) and can lead to heart failure. The major objective of the present study was to …
Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats
S Mitsuyama, D Takeshita, K Obata, GX Zhang… - Journal of Molecular and …, 2013 - Elsevier
Overexpression of cardiac sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) has been
suggested as a strategic intervention for cardiac failure. However, its benefit in wild-type …
suggested as a strategic intervention for cardiac failure. However, its benefit in wild-type …
[HTML][HTML] Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats
Background The additive effects of obesity and metabolic syndrome on left ventricular (LV)
maladaptive remodeling and function in hypertension are not characterized. Methods We …
maladaptive remodeling and function in hypertension are not characterized. Methods We …
[HTML][HTML] Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway
X Tan, J Li, X Wang, N Chen, B Cai… - … Journal of Biological …, 2011 - ncbi.nlm.nih.gov
Pathological cardiac hypertrophy induced by adrenergic overactivation can subsequently
develop to heart failure which remains as a leading cause of mortality worldwide …
develop to heart failure which remains as a leading cause of mortality worldwide …
[HTML][HTML] Administration of losartan preserves cardiomyocyte size and prevents myocardial dysfunction in tail-suspended mice by inhibiting p47phox phosphorylation …
L Liang, W Yuan, L Qu, H Li, L Zhang, GC Fan… - Journal of Translational …, 2019 - Springer
Background Spaceflight or microgravity conditions cause myocardial atrophy and
dysfunction, contributing to post-flight orthostatic intolerance. However, the underlying …
dysfunction, contributing to post-flight orthostatic intolerance. However, the underlying …
[HTML][HTML] Calcium inhibitor inhibits high glucose‑induced hypertrophy of H9C2 cells
X Xu, L Ruan, X Tian, F Pan… - Molecular Medicine …, 2020 - spandidos-publications.com
The aim of the present study was to explore whether the hypertrophy of H9C2
cardiomyocytes was induced by high glucose, to investigate whether the calcium channel …
cardiomyocytes was induced by high glucose, to investigate whether the calcium channel …
[HTML][HTML] Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca2+ cycling proteins
Background Cardiac hypertrophy is a compensatory stage of the heart in response to stress
such as pressure overload (PO), which can develop into heart failure (HF) if left untreated …
such as pressure overload (PO), which can develop into heart failure (HF) if left untreated …
[HTML][HTML] Protective effects of sacubitril/valsartan on cardiac fibrosis and function in rats with experimental myocardial infarction involves inhibition of collagen synthesis …
M Wu, Y Guo, Y Wu, K Xu, L Lin - Frontiers in Pharmacology, 2021 - frontiersin.org
Objectives: To investigate the effect and mechanism of sacubitril/valsartan on myocardial
fibrosis in rats following experimental myocardial infarction and in TGF-β1-treated …
fibrosis in rats following experimental myocardial infarction and in TGF-β1-treated …
Angiotensin II–induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats
Y Ikeda, T Nakamura, H Takano, H Kimura… - Journal of Laboratory …, 2000 - Elsevier
Angiotensin-converting enzyme inhibitors (ACEIs) cause regression of hypertensive left
ventricular hypertrophy (LVH) by reducing angiotensin II, increasing bradykinin, or both. The …
ventricular hypertrophy (LVH) by reducing angiotensin II, increasing bradykinin, or both. The …